CAR T-cell therapy not approved in Scotland
Tisagenlecleucel (Kymriah®) not available for use on the NHS in Scotland
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
Tisagenlecleucel (Kymriah®) not available for use on the NHS in Scotland
British Association of Dermatologists publishes new guidelines for the management of primary cutaneous lymphomas
The Scottish Medicines Consortium is not recommending axicabtagene ciloleucel (Yescarta®) for use within NHS Scotland
New CAR-T cell therapies will be available for selected people with relapsed or refractory large B‑cell lymphoma
Venetoclax plus rituximab is now available on the NHS for adults with relapsed or refractory CLL
Mogamulizumab licensed for the treatment of mycosis fungoides or Sézary syndrome (SS)
Have your say on brentuximab vedotin for cutaneous T-cell lymphoma
Have your say on bendamustine with rituximab for relapsed low-grade non-Hodgkin lymphoma.
New guidelines give a clear treatment pathway for people with primary CNS lymphoma
Stephen Scowcroft, our Business Development Manager, reports back from the European Society of Medical Oncology (ESMO) Congress 2018 #ESMO18.